HIGHLIGHTS
- who: Sandra Lara from the Department of Cell and Molecular Biology, Uppsala University, Uppsala have published the Article: Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma, in the Journal: (JOURNAL)
- what: The aim of this study was to systematically evaluate factors influencing complement-mediated tumor cell killing by RTX. The authors show for the first time that tumor CD20/CD59 expression ratio, tumor architecture and choice of isotype synergistically influence RTX-mediated CDC activity in B-cell lymphoma.
- how: To systematically define features that can affect . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.